MDMA ("Ecstasy") --a dangerous drug or psychotherapeutic drug?
Szukaj, M.
Der Nervenarzt 65(11): 802-805
1994
ISSN/ISBN: 0028-2804 PMID: 7816160 Document Number: 426238
Abuse of 3,4-methylenedioxymethamphetamine (MDMA) is increasing, as is the number of deaths associated with "ecstasy". The history, effects and side effects of this controversial psychotropic substance are presented. Its relevance for clinical practice is shown.
Document emailed within 1 workday
Related Documents
Prat, A.; Montero, M.; Reig, R.; Sanz, P. 1991: MDMA ("ecstasy"): a currently used drug in Spain Revista Clinica Espanola 188(2): 106-108Chishiro, T.; Matsubara, M.; Kiuchi, S. 2003: Two cases of "Ecstasy (MDMA)" poisoning Chudoku Kenkyu: Chudoku Kenkyukai Jun Kikanshi 16(4): 463-464
Dowling, G.P.; McDonough, E.T.; Bost, R.O. 1987: 'Eve' and 'Ecstasy'. A report of five deaths associated with the use of MDEA and MDMA JAMA 257(12): 1615-1617
Ezoubi, S.; Kahal, H.; Waring, W.S. 2016: Pneumomediastinum as a complication of MDMA (3,4-methylenedioxymetamfetamine, Ecstasy) ingestion Acute Medicine 15(3): 152-156
O'Connor, A.; Cluroe, A.; Couch, R.; Galler, L.; Lawrence, J.; Synek, B. 1999: Death from hyponatraemia-induced cerebral oedema associated with MDMA ("Ecstasy") use New Zealand Medical Journal 112(1091): 255-256
Rukskul, P. 2005: Ecstasy (MDMA) ingestion related with severe hyponatremia in patients with mild head injury Journal of the Medical Association of Thailand 88(1): 41-44
Sjöqvist, F. 1980: The measurement of psychotherapeutic drug concentrations in biological fluids: utility in clinical trials and practice. Overview by drug classes--clinical monitoring of tricyclic antidepressant plasma concentrations Psychopharmacology Bulletin 16(3): 21-25
De Visme, P.G. 1998: Neurotoxicity of the drug Ecstasy. Functional consequences of serotonergic hypoactivity Ugeskrift for Laeger 160(42): 6088-6091
Aagaard, G.N. 1973: Drug spotlight on psychotherapeutic drugs Annals of Internal Medicine 79(1): 130
Wilkins, C.; Bhatta, K.; Pledger, M.; Casswell, S. 2003: Ecstasy use in New Zealand: findings from the 1998 and 2001 National Drug Surveys New Zealand Medical Journal 116(1171): U383
Andersson, M.L.; Böttiger, Y.; Lindh, J.D.; Wettermark, B.; Eiermann, B. 2013: Impact of the drug-drug interaction database SFINX on prevalence of potentially serious drug-drug interactions in primary health care European Journal of Clinical Pharmacology 69(3): 565-571
Van Meerbeeck, P. 1982: Drugs and drug addiction. Psychotherapeutic treatment Journal de Pharmacie de Belgique 37(5): 365-369
Baconcini, C. 1971: Psychodynamic and psychotherapeutic aspects of drug addiction Rivista Sperimentale di Freniatria E Medicina Legale Delle Alienazioni Mentali 95(6): 1229-1235
Verdejo-García, A.; Pérez-García, M.; Sánchez-Barrera, M.; Rodriguez-Fernández, A.; Gómez-Río, M. 2007: Neuroimaging and drug addiction: neuroanatomical correlates of cocaine, opiates, cannabis and ecstasy abuse Revista de Neurologia 44(7): 432-439
Torsti, P. 1971: Is acetylsalicylic acid a dangerous drug? Duodecim; Laaketieteellinen Aikakauskirja 87(7): 492-494
De Benedetti, E.; Urban, P. 2007: Are drug-eluting stents dangerous? Revue Medicale Suisse 3(102): 656-658
Astrup, N. 1992: India: an expensive and dangerous drug Sygeplejersken 92(51): 36-38
Diamond, J.; Leeming, J. 1995: Chloramphenicol eye drops: a dangerous drug? Practitioner 239(1555): 608-611
Persson, S.A.; Eriksson, A.; Hallgren, N.; Eklund, A.; Berkowicz, A.; Druid, H. 2001: GHB--dangerous, addictive and uncontrollable "party drug" Lakartidningen 98(38): 4026
Markus, L. 2008: Flunitrazepame--report based on experience with a dangerous drug MMW Fortschritte der Medizin 150 Suppl. 1: 27-30